Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide begins working from your very first dose, but meaningful weight loss typically becomes noticeable after four to eight weeks. Most people see the clearest changes once they reach a higher maintenance dose, which can take several months of gradual titration. These are prescription-only medicines that require a clinical assessment before a prescriber can determine whether they're right for you. If you're trying to make sense of the timeline, here's what the clinical picture actually looks like.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Yes, though the changes are subtle at first. Semaglutide is a GLP-1 receptor agonist, meaning it mimics a gut hormone that signals fullness to the brain, slows how quickly the stomach empties, and damps down appetite. Those effects are present from the very first injection. What most people notice early on is that they feel full sooner at meals and think about food less between them. The scales may not shift dramatically in week one or two, and that's expected.
Treatment starts at a low dose specifically to let your body adjust. That first-dose caution isn't there to hold back results — it's there to reduce the nausea and digestive discomfort that can come with starting any GLP-1 medicine. The mechanism behind semaglutide means appetite suppression is genuine from the outset; the titration schedule just manages how intensely it hits.
A question our prescribers hear most weeks is: "I'm on the starter dose and nothing seems to be happening, is it working?" Almost always, something is. The full effect unfolds as the dose rises.
For many people, the four-to-twelve-week window is when weight loss becomes more tangible. By this point the dose has usually increased at least once, appetite suppression is stronger, and calorie intake has fallen more consistently. Clothes may feel looser before the number on the scale moves as dramatically as expected, partly because of changes in fluid balance and activity levels.
The STEP 1 trial (published in the New England Journal of Medicine) followed 1,961 adults over 68 weeks at the 2.4mg maintenance dose of semaglutide. Average weight reduction was around 15%. That figure accumulated gradually, with participants continuing to lose weight through much of the trial period rather than dropping quickly and flattening out.
It's worth reading more about the typical semaglutide timeline week by week if you want a closer look at when different effects tend to peak. The short version: steady progress over months, not a dramatic overnight shift.
Not exactly, but weight loss does slow. After roughly 60–72 weeks at a stable maintenance dose, most people reach a new set point where the body adapts to the lower calorie intake and weight plateaus. This is a well-documented biological pattern, not a sign the medicine has become ineffective. Appetite suppression is still present; the deficit has simply narrowed as the body recalibrates its energy expenditure.
The NHS patient guidance on semaglutide and tirzepatide explains that these medicines work best alongside a reduced-calorie diet and increased physical activity, both of which remain important throughout treatment, not just at the start. If your progress stalls, the right conversation is with your prescriber, who can review whether a dose adjustment or other changes make clinical sense.
Stopping treatment abruptly often reverses weight loss over time. If you're thinking about that question, our page on stopping Wegovy suddenly covers what the evidence says and what to discuss with your clinical team.
Starting weight, metabolic rate, how consistently the medicine is taken, diet quality, activity levels, and how quickly you can tolerate dose increases all play a role. People who experience significant nausea may stay on lower doses for longer, which delays the point at which the stronger appetite-suppression effect kicks in, but titrating more slowly is sometimes the right clinical choice, not a compromise.
The NHS semaglutide medicines page notes that the medicine is taken once a week and that missing doses or taking them irregularly can reduce its effectiveness. Consistency matters more than people often expect with a once-weekly injection, and if you're wondering how to fit injections around a busy schedule, our guide on taking Wegovy to work covers practical ways to manage your doses on working days. There's also individual biological variation: two people on the same dose, same diet, same activity level can see different results, and that's genuinely normal.
For a fuller picture of how the medicine fits into a private treatment pathway, the Wegovy overview covers eligibility, the licensed doses available in the UK, and what clinical review looks like at each stage. Cost is sometimes part of the planning conversation too; the Wegovy pricing page sets out what private treatment typically involves financially.
If you'd like to discuss your own circumstances with a prescriber, starting a free consultation with our clinical team is the straightforward next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.